Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Sun Life Financial Inc. Common Stock — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.71 (market cap $1.66B), while Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.10B). The key difference: Sun Life Financial Inc. Common Stock is far larger — about 26× Nuvation Bio Inc. Class A Common Stock's market cap, and Sun Life Financial Inc. Common Stock pays a 3.48% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 6 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| NUVB | SLF | |
|---|---|---|
Market Cap | $1.66B | $43.10B |
Volume | 7,608,075 | 448,420 |
Sector | Health | Financials |
52-Week High | $9.54 | $84.07 |
52-Week Low | $3.41 | $57.60 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.25B | $44.83B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
